All Pharma News
In less than 3 months, AbbVie closes $10.1B buyout of ImmunoGen

In less than 3 months, AbbVie closes $10.1B buyout of ImmunoGen
FIERCE PHARMA
12 Feb 2024
Share Share
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BUSINESSWIRE
01 Feb 2024
Share Share
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BUSINESSWIRE
03 Jan 2024
Share Share
Filing reveals how AbbVie`s $10B ImmunoGen offer won out

Filing reveals how AbbVie`s $10B ImmunoGen offer won out
Zoey Becker FIERCE PHARMA
02 Jan 2024
Share Share
ImmunoGen Presents Findings from Phase 1b/2 Study of Pivekimab Sunirine at ASH

ImmunoGen Presents Findings from Phase 1b/2 Study of Pivekimab Sunirine at ASH
BUSINESSWIRE
10 Dec 2023
Share Share
FDA Grants Priority Review of ImmunoGen’s Supplemental BLA for ELAHERE

FDA Grants Priority Review of ImmunoGen’s Supplemental BLA for ELAHERE
BUSINESSWIRE
05 Dec 2023
Share Share
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BUSINESSWIRE
01 Dec 2023
Share Share
AbbVie to buy ImmunoGen for $10.1 billion to boost cancer drug portfolio

AbbVie to buy ImmunoGen for $10.1 billion to boost cancer drug portfolio
REUTERS
01 Dec 2023
Share Share
ImmunoGen Announces Webcast of Presentation

ImmunoGen Announces Webcast of Presentation
BUSINESSWIRE
02 Nov 2023
Share Share
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BUSINESSWIRE
01 Nov 2023
Share Share